REDWOOD CITY, CA – June 22, 2017 – PaxVax, Inc., a fully integrated specialty vaccine company focused on travel, and TerahVax, a vaccine specialized company launching vaccine products in Asia, announced today that they have entered into a marketing and distribution agreement for PaxVax specialty vaccine product, Vivotif® (Typhoid Vaccine Live Oral Ty21a), in South Korea. The parties expect the product to be licensed and available for distribution in South Korea in 2018.
“PaxVax is pleased to partner with TerahVax to expand the availability of Vivotif to South Korea,” said Nima Farzan, Chief Executive Officer and President of PaxVax. “This partnership is a reflection of our mutual commitment and dedication to helping protect travelers around the globe from infectious diseases, such as typhoid fever.”
Typhoid fever is still common in the developing world, where it affects about 21.5 million people each year. According to the CDC, the highest risk for typhoid is in South Asia.1 If untreated, typhoid fever persists for three weeks to one month. Death occurs in between 10 percent and 30 percent of untreated cases.
“We are delighted to work with PaxVax and launch the company’s high-quality vaccine products into the Korean market,” said YoungJin Chung, President and CEO of TerahVax.
PaxVax is a leading independent vaccine company that is devoted to bringing specialty vaccines that protect against overlooked infectious diseases to market, providing effective tools for health care providers who serve the 100 million people per year who travel to countries where these diseases are present. It commercializes vaccines for typhoid fever (Vivotif®) and cholera (Vaxchora®), and has a robust pipeline with vaccines at various stages of preclinical and clinical development for adenovirus, chikungunya, hepatitis A, HIV and Zika. As part of its social mission, PaxVax is also committed to making its vaccines available for use in developing world and increasing access to vaccines for the people who need them most. More information is available at http://www.paxvax.com/.
The mission of TerahVax is to prevent and eradicate infectious diseases and launch high-quality vaccine products in market. TerahVax makes its efforts to improve prevention healthcare and has been investing to launch vaccine products through exclusive partnerships with companies specialized in research and development in this specific field. The company does its best to take the lead in providing those who need vaccinations with various vaccine products and possessing vaccines at clinical-stage development. TerahVax believes that health is the greatest value of all and its value is to preserve and improve health.
1 Centers for Disease Control and Prevention. Typhoid Fever Fact Sheet. July 2016. https://www.cdc.gov/typhoid-fever/. Accessed May 2017.